Valhalla, New York 10595

  • Chronic Myelogenous Leukemia

Purpose:

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.


Study summary:

Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.


Criteria:

Inclusion Criteria: - Relapsed or refractory acute lymphoblastic leukemia, - Burkitts leukemia/lymphoma, - Lymphoid blastic CML, - Lymphoblastic lymphoma.


NCT ID:

NCT01513603


Primary Contact:

Principal Investigator
Karen Seiter, MD
New York Medical College

Karen Seiter, MD
Phone: 914 493 7514
Email: karen_seiter@nymc.edu


Backup Contact:

Email: nasir_ahmed@nymc.edu
Nasir Ahmed, MD
Phone: 914 493 7514


Location Contact:

Valhalla, New York 10595
United States

Karen Seiter, MD
Phone: 914-493-7514
Email: karen_seiter@nymc.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: December 07, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.